R&D channel feed – Endpoints News

R&D channel feed

Alise Reicin recruits GNF vet Peter McNamara to head research at Tim Springer's latest startup

5 years ago

FDA authorizes Vir-GSK antibody as variants threaten Eli Lilly mAb

5 years ago

Days after FDA clears C3 drug, Apellis spotlights ex-US PhIII win among patients who haven't taken Soliris

5 years ago

Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis

5 years ago

A top analyst sees 'inflection point' in the other big vaccine race taking pharma by storm

5 years ago

FDA may require bispecific antibodies to be compared with monospecific products

5 years ago

Boehringer embarks on a PhIII odyssey for a failed Alzheimer's drug — now refocused on schizophrenia with new trial tech and a ‘breakthrough’ at the FDA

5 years ago

Bipartisan House bill seeks new $30B ‘BioBonds’ loan program to reinvigorate clinical trials

5 years ago

NGM concedes key failure for their lead NASH drug, closing the door on a pivotal followup — and asking analysts to look past the wreckage into the pipeline

5 years ago

With its dengue vaccine in the regulatory queue, Takeda outlines longterm followup data that it says keep it out of Dengvaxia's shadow

5 years ago

Novartis, BeiGene's PD-(L)1 play takes home another win in late-stage data, adding some heft to its market potential

5 years ago

In tight next-gen pneumococcal vaccine race with Pfizer, Merck reads out topline pediatric data

5 years ago

FDA revises and expands draft guidance on adjusting for covariates in RCTs

5 years ago

#ASCO21: Watch out Bristol Myers, J&J is back at ASCO with some competitive BCMA CAR-T data

5 years ago

House committee grills Emergent CEO Bob Kramer over J&J vaccine debacle, ill-timed stock sale

5 years ago

#ASCO21: Bristol Myers takes home the win in 1st late-stage study for LAG-3 pathway, setting up a US filing

5 years ago

Eli Lilly wraps up fifth and final tirzepatide PhIII trial, claiming a win over Sanofi's Lantus. The FDA awaits

5 years ago

#ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

5 years ago

#ASCO21: Takeda fleshes out case for oral EGFR drug with follow-up pivotal data in non-small cell lung cancer

5 years ago

#ASCO21: With Bristol Myers set for its own big LAG-3 update at ASCO, Merck touts early success for a potential competitor

5 years ago

#ASCO21: EQRx's cheaper EGFR drug busts Iressa in head-to-head test, and a US filing could be right down the road

5 years ago

#ASCO21: Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone

5 years ago

#ASCO21: Adaptimmune gives first glimpse at pivotal data for what they hope will be first approved TCR

5 years ago

#ASCO21: Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach

5 years ago

First page Previous page 169 170 171172173 174 175 Next page Last page